FDA accepts exenatide NDA

FDA accepted for filing an NDA from Amylin (AMLN) and partner Eli Lilly (LLY) for exenatide synthetic exendin-4 to treat Type II diabetes. The PDUFA date is April 30, 2005. On Wednesday, AMLN was up $...